Sanara MedTech Inc has a consensus price target of $51.5, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Cantor Fitzgerald, and Cantor Fitzgerald on March 27, 2024, February 6, 2024, and November 15, 2023. With an average price target of $47.33 between Cantor Fitzgerald, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 46.95% upside for Sanara MedTech Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/27/2024 | SMTI | Buy Now | Sanara MedTech | $32.21 | 36.6% | Cantor Fitzgerald | Ross Osborn | $49 → $44 | Maintains | Overweight | Get Alert |
02/06/2024 | SMTI | Buy Now | Sanara MedTech | $32.21 | 52.13% | Cantor Fitzgerald | Ross Osborn | → $49 | Reiterates | Overweight → Overweight | Get Alert |
11/15/2023 | SMTI | Buy Now | Sanara MedTech | $32.21 | 52.13% | Cantor Fitzgerald | Ross Osborn | $59 → $49 | Maintains | Overweight | Get Alert |
09/26/2023 | SMTI | Buy Now | Sanara MedTech | $32.21 | 83.17% | Cantor Fitzgerald | Brandon Folkes | → $59 | Reiterates | Overweight → Overweight | Get Alert |
08/22/2023 | SMTI | Buy Now | Sanara MedTech | $32.21 | 83.17% | Cantor Fitzgerald | Brandon Folkes | → $59 | Reiterates | Overweight → Overweight | Get Alert |
08/17/2023 | SMTI | Buy Now | Sanara MedTech | $32.21 | 83.17% | Cantor Fitzgerald | Brandon Folkes | → $59 | Reiterates | Overweight → Overweight | Get Alert |
06/30/2021 | SMTI | Buy Now | Sanara MedTech | $32.21 | 39.71% | Cantor Fitzgerald | Brandon Folkes | — | Initiates | → Overweight | Get Alert |
The latest price target for Sanara MedTech (NASDAQ: SMTI) was reported by Cantor Fitzgerald on March 27, 2024. The analyst firm set a price target for $44.00 expecting SMTI to rise to within 12 months (a possible 36.60% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Sanara MedTech (NASDAQ: SMTI) was provided by Cantor Fitzgerald, and Sanara MedTech maintained their overweight rating.
There is no last upgrade for Sanara MedTech.
There is no last downgrade for Sanara MedTech.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sanara MedTech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sanara MedTech was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
While ratings are subjective and will change, the latest Sanara MedTech (SMTI) rating was a maintained with a price target of $49.00 to $44.00. The current price Sanara MedTech (SMTI) is trading at is $32.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.